Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 254 of 5804
-
Can a smartphone app help teens fight suicidal thoughts?
Symptom relief Recruiting nowSuicide risk has increased among youth in underserved communities, where access to mental healthcare is limited. To address this need, the investigator team plans to evaluate the preliminary efficacy of a brief, low-cost, culturally responsive digital intervention for ethnically …
Phase: NA • Sponsor: Albert Einstein College of Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
Can special glasses or eyedrops stop kids' eyesight from getting worse?
Disease control Recruiting nowTo date, randomized trials of low-concentration atropine eyedrops and specially designed spectacle lenses to slow the progression of myopia are limited in number and results are inconsistent in non-Asian children. Although results of some recent randomized clinical trials outsid…
Phase: PHASE3 • Sponsor: Jaeb Center for Health Research • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New injections aim to shrink Hard-to-Treat skin tumors
Disease control Recruiting nowOpen label, randomized study in patients with LaBCC not eligible or refusing surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board. The primary objective of the study is to evaluate the efficacy of L19IL2 or L19TNF or L19IL2/L19TNF, the…
Phase: PHASE2 • Sponsor: Philogen S.p.A. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Personalized cancer treatment: matching drugs to tumor DNA may delay disease worsening
Disease control Not yet recruitingThe goal of this clinical trial is to learn if drugs that are matched to tumor DNA mutations work to treat metastatic solid cancers in adults. The main questions it aims to answer are: Is tumor worsening delayed for a longer period of time if patients take drugs that match DNA m…
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New shot could tame tough eczema Flare-Ups
Disease control Not yet recruitingStudy of ADSTEM Injection for Patients with Moderate to Severe Subacute and Chronic Atopic Dermatitis
Phase: PHASE3 • Sponsor: EHL Bio Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Zapping resistant spots: radiation may buy more time for lung cancer patients on targeted drugs
Disease control Not yet recruitingThis is an open-label, prospective single arm Phase II trial that investigates the role of ablative stereotactic body radiation therapy (SBRT) in oncogene driven metastatic non-small cell lung cancer (mNSCLC) patients with oligoprogressive disease (OPD) on targeted therapy (TKI) …
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New combo therapy aims to shrink advanced liver and kidney tumors
Disease control Not yet recruitingThis is a Phase II study being done at several hospitals without using a placebo. It will look at how safe and tolerable the drug WGI-0301 is when given together with nivolumab, how the body processes and responds to WGI-0301, and whether this combination shows early signs of wor…
Phase: PHASE2 • Sponsor: Zhejiang Haichang Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for Tough-to-Treat myeloma: phase 3 trial launches
Disease control Not yet recruitingThis study is a randomized, open-label, multicenter Phase III clinical trial involving patients with relapsed/refractory multiple myeloma. The estimated total sample size is 260 cases, who will be randomly assigned in a 1:1 ratio to the test group and the control group. The prima…
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
MRI-Guided prostate cancer treatment cuts radiation to just 2 doses
Disease control Not yet recruitingA number of recent studies have successfully reduced the number of radiotherapy treatments used for prostate cancer from 39 daily treatments to as little as 5 treatments. This study is designed to determine how tumors inside the prostate respond during these 5 treatments on magne…
Phase: PHASE2 • Sponsor: AHS Cancer Control Alberta • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New combo therapy aims to tackle advanced liver cancer
Disease control Not yet recruitingTo provide evidence-based medical evidence for the optimized combination strategy of local and systemic therapies.
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New heart catheter aims to tame Life-Threatening rhythm disorder
Disease control Not yet recruitingSphere VT is a prospective, multi-center, single-arm, unblinded pivotal clinical study. Adult subjects with recurrent, sustained, monomorphic ventricular tachycardia (MMVT) due to prior myocardial infarction (MI) will be enrolled and treated with the Sphere-9 Catheter and Affera …
Phase: NA • Sponsor: Medtronic Cardiac Ablation Solutions • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New trial aims to save rectums in early cancer patients
Disease control Not yet recruitingSafety and Efficacy of Organ Preservation Treatment for Stage I Rectal Cancer: Optimization of Consolidation Chemotherapy Before Local Excision After Neoadjuvant Chemoradiotherapy (OPTION); A Multi-center, Prospective, Randomized Trial The goal of this clinical trial is to find …
Phase: NA • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug combo aims to boost surgery success for esophageal cancer
Disease control Not yet recruitingEvaluating the efficacy and safety of SHR-1701 combined with chemotherapy for the perioperative treatment of locally advanced resectable Siewert type II adenocarcinoma of the esophagogastric junction.
Phase: PHASE2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Genetic test may guide chemo choice for pancreatic cancer patients
Disease control Not yet recruitingPancreatic ductal adenocarcinoma (PDAC) exhibits significant heterogeneity, making the optimal choice of chemotherapy challenging. While targeted therapies benefit from companion biomarkers, few tools exist to guide the selection of cytotoxic chemotherapy. Transcriptomic signatur…
Phase: PHASE2 • Sponsor: Federation Francophone de Cancerologie Digestive • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug cocktail shows promise for Hard-to-Treat breast cancer before surgery
Disease control Not yet recruitingThis is a phase II, single-arm, prospective exploratory study to evaluate the efficacy and safety of neoadjuvant dalpiciclib (a CDK4/6 inhibitor) plus an aromatase inhibitor (AI) followed by SHR-A1811 (an anti-HER2 antibody-drug conjugate) in patients with intermediate-to-high ri…
Phase: PHASE2 • Sponsor: Tang-Du Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
AI breakthrough could spot hidden heart attacks in patients with tricky ECG patterns
Diagnosis Recruiting nowThis study investigates a new way to diagnose severe heart attacks in patients who have a specific electrical heart pattern called a Left Bundle Branch Block (LBBB). When patients present to the emergency department with chest pain, doctors routinely perform an electrocardiogram …
Sponsor: Konya City Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
New drug cocktail targets Hard-to-Treat lung cancer
Disease control Not yet recruitingThis clinical trial evaluates the combination of olomorasib and pembrolizumab as a first-line treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC) that has a Kirsten Rat Sarcoma Virus (KRAS) G12C mutation and a programmed death-ligand (PD-L1) scor…
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Painless blood test could replace bone marrow biopsy for MPN patients
Diagnosis Not yet recruitingThis observational, multi-center study aims to collect data to develop a novel, minimally invasive diagnostic tool for myeloproliferative neoplasms (MPN) based on peripheral blood (PB) profiling of circulating hematopoietic stem and progenitor cells (cHSPCs) using single-cell RNA…
Sponsor: Weizmann Institute of Science • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on breast cancer
Disease control Recruiting nowThe purpose of this study is to assess the feasibility, safety and efficacy of multiple 4th generation CAR-T cells targeting Her2, GD2, and CD44v6 surface antigen in breast cancer. Another goal of the study is to learn more about the activities of the multi-CAR T cells and their …
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
First-in-Class cancer drug targets Hard-to-Treat tumors
Disease control Not yet recruitingThis study is to evaluate the safety and tolerability to determine (i) the recommended Phase 2 dose (RP2D) of VMD-102 (Phase 1), and (ii) preliminary anti-tumor efficacy (Phase 2), in participants with advanced HCC, metastatic uveal melanoma (MUM), renal cell carcinoma (RCC), non…
Phase: PHASE1, PHASE2 • Sponsor: VM Discovery, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC